ScreenerHero

BDRX Biodexa Pharmaceuticals Plc

NAS · US · Healthcare · Biotechnology · biodexapharma.com
0.5638USD-5.26%Mkt Cap: 509712 $P/E: 0.01

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 di…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap509.71K USD
Enterprise Value-2.79M USD
Revenue (TTM)—
Gross Profit-3.96M USD
Net Income (TTM)-6.38M USD
Revenue/Share—
Last Price0.5638 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees11
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)0.01
P/E (Forward)Infinity
PEG—
EV/EBITDA0.32
EV/Revenue—
P/S—
P/B0.03
EPS (TTM)64.35
EPS (Forward)0.00
52W Range
0.53470% of range59.40
52W High59.40 USD
52W Low0.5347 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-55.98%
ROA-35.12%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.59M USD
CapEx (TTM)691.00K USD
FCF Margin—
FCF Yield-806.41%
Net Debt-3.23M USD
Net Debt/EBITDA0.37
Balance Sheet
Debt/Equity0.01
Current Ratio2.41
Quick Ratio2.41
Book Value/Sh17.06 USD
Cash/Share4.33 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateMar 3, 2020
Splits
Last Split1:5
Split DateApr 6, 2026
Analyst Consensus
Rating0.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)8.919 USD
Upside (mean)+1481.9%
Target Range8.919 USD – 8.919 USD
# Analysts1
Ownership
Shares Out.904.07K
Float684.07K
Insiders0.00%
Institutions1.61%
Short Interest
Short Ratio0.0d
Short % Float26.42%
Short % Out.26.42%
Shares Short271.87K
Short (prev mo.)4.81K
Technical
SMA 501.081 (-47.9%)
SMA 2004.461 (-87.4%)
Beta1.28
S&P 52W Chg16.45%
Avg Vol (30d)5.22M
Avg Vol (10d)239.46K
Technical Indicators
RSI (14)34.4
MACD-0.1684
MACD Signal-0.1825
MACD Hist.+0.0141
BB Upper1.207 USD
BB Middle0.7595 USD
BB Lower0.3124 USD
BB Width117.75%
ATR (14)0.1296 USD
Vol Ratio (20d)0.02x